Improved survival of HIV patients facilitates heart disease research

July 27, 2015

WASHINGTON (July 27, 2015) - The improved survival rate of HIV patients in sub-Saharan Africa due to effective treatment programs is increasing the ability of researchers in Africa to study the impacts of cardiovascular disease in HIV patients, according to a guest editor page published today in the Journal of the American College of Cardiology.

According to guest editor Pravin Manga, M.B.B.C.H., Ph.D., of the University of Witwatersrand in Johannesburg, some countries in sub-Saharan Africa, like South Africa, have created highly active antiretroviral treatment programs that reach a number of HIV patients; but many developing nations with limited resources are unable to treat as many patients with antiretroviral therapy. Highly active antiretroviral treatment is the standard treatment for HIV; it consists of a combination of at least three drugs taken in a specific order to suppress HIV replication. This treatment disparity has created two different types of HIV patients in Africa with different challenges for cardiovascular disease, which provides an opportunity for research.

Many countries in sub-Saharan Africa are a long way from providing an effective antiretroviral therapy treatment program for HIV patients. However, as antiretroviral therapy is associated with a significant reduction in HIV-related cardiovascular disease and improved life expectancy, there has been support for campaigns to get universal treatment programs in place.

Studies in developed countries show an increase in cardiovascular events due to coronary artery disease in HIV patients. It was expected that because of the large HIV population in sub-Saharan Africa that there would be an increase in coronary artery disease; however, this has not happened. The reason for this is unknown but may be due to a much younger population in the region and even a low use of protease inhibitors - one of the antiviral drugs used to treat HIV, according to Manga. It has been found that highly active antiretroviral treatment is associated with an almost 50 percent reduction in the prevalence of HIV-related cardiomyopathy.

"The global burden of disease has dramatically shifted from communicable, maternal, perinatal, and nutritional causes to noncommunicable diseases," said Valentin Fuster, M.D., Ph.D., editor-in-chief of the Journal of the American College of Cardiology. "As Dr. Manga eloquently describes, sub-Saharan Africa has been burdened with terrible mortality rates from HIV/AIDS as a result of a lack of antiretroviral treatments. Now, that these therapies have improved distribution throughout the region, the clinical and research communities are faced with new challenges of treating patients with both HIV and various cardiovascular diseases."

Most of the major research in sub-Saharan Africa has focused on the prevention and treatment of HIV with very little focused specifically on the impact of HIV on cardiovascular disease. The improved survival of patients being treated in some countries with antiretroviral therapy will provide a platform for researchers in Africa to study cardiovascular disease in HIV patients -those who being treated with antiretroviral therapy and those who are not.
The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, promotes cardiovascular research and bestows credentials on cardiovascular specialists who meet stringent qualifications. For more information, visit

American College of Cardiology

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to